OBJECTIVE: To report headache (HA) data collected from subjects in a longitudinal study of human immunodeficiency virus (HIV)-1 and the central nervous system (CNS) DESIGN/ METHODS: Baseline data from 229 ambulatory HIV-seropositive (HIV+) and 53 seronegative control subjects were analyzed. Subjects were classified by the presence or absence of HIV-1-associated HAs and HIV-1-associated systemic and neurologic disease. Subjects were followed longitudinally for up to 5 years. RESULTS: In the cross-sectional analysis, significant associations were observed between HIV-1-associated HAs and (1) anxiety and depression, and (2) a history of drug use, psychiatric disease, and non-HIV-1 neurologic disease. No significant differences in laboratory values were found between subjects with HIV-1-associated HA compared with those without HA. When HIV+ subjects were followed longitudinally, onset of new HIV-1-associated systemic or neurologic disease over 1 year was not predicted by the presence of an HIV-1-associated HA at baseline. CONCLUSION: Headaches are common in HIV+ persons at all stages of disease. Presence of HIV-1-associated HAs at baseline were not associated with neurologic disease progression over 1 year of follow-up in our sample.
OBJECTIVE: To report headache (HA) data collected from subjects in a longitudinal study of human immunodeficiency virus (HIV)-1 and the central nervous system (CNS) DESIGN/ METHODS: Baseline data from 229 ambulatory HIV-seropositive (HIV+) and 53 seronegative control subjects were analyzed. Subjects were classified by the presence or absence of HIV-1-associated HAs and HIV-1-associated systemic and neurologic disease. Subjects were followed longitudinally for up to 5 years. RESULTS: In the cross-sectional analysis, significant associations were observed between HIV-1-associated HAs and (1) anxiety and depression, and (2) a history of drug use, psychiatric disease, and non-HIV-1 neurologic disease. No significant differences in laboratory values were found between subjects with HIV-1-associated HA compared with those without HA. When HIV+ subjects were followed longitudinally, onset of new HIV-1-associated systemic or neurologic disease over 1 year was not predicted by the presence of an HIV-1-associated HA at baseline. CONCLUSION:Headaches are common in HIV+ persons at all stages of disease. Presence of HIV-1-associated HAs at baseline were not associated with neurologic disease progression over 1 year of follow-up in our sample.
Authors: Whitney Scott; Chinar Arkuter; Kitty Kioskli; Harriet Kemp; Lance M McCracken; Andrew S C Rice; Amanda C de C Williams Journal: Pain Date: 2018-12 Impact factor: 6.961